iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study

Amyotrophic Lateral Sclerosis Clinical Trial

Official title:

Phase 1/2 Study of Bosutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04744532
• Other study ID #: WI240618
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: March 19, 2019
• Est. completion date: March 31, 2024

Study information

• Verified date: February 2023
• Source: Kyoto University
• Contact: Haruhisa Inoue
• Phone: 0753667360
• Email: prj-als_bosutinib[@]cira.kyoto-u.ac.jp
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study consists of a phase 1 part and a phase 2 part.

Phase 1 part:

This is a phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of bosutinib to determine the maximum tolerated dose(MTD) and a recommended phase 2 dose (RP2D) of bosutinib for treatment of ALS patients. Also, efficacy will be evaluated exploratory.

Phase 2 part:

This is an open label, multicenter, phase 2 part whose purpose is to evaluate the efficacy exploratorily and the long-term (for 24 weeks) safety of bosutinib for the treatment of ALS patients.

Description:

Phase 1 part:

The study consists of a 12-week observation period, a 1-week (acceptable window: 5-9 days) transitional period, a 12-week study treatment period, and a 4-week follow-up period. Subjects who have been receiving riluzole since before the enrollment are allowed to continuously receive riluzole during the 12-week observation period (with the dosage remaining unchanged), and stop receiving riluzole from the beginning of the 1-week (acceptable window: 5-9 days) transitional period. After the completion of the transitional period, subjects whose total ALSFRS-R score decreased by 1 to 3 points during the 12-week observation period will receive bosutinib for 12 weeks to evaluate the safety and tolerability of bosutinib in ALS patients. All ALS drugs including riluzole will be prohibited during the bosutinib treatment period.

In this study, 3 to 6 ALS patients will be enrolled in each of the 4 bosutinib dose lelvels [100 mg/day (dose level 1), 200 mg/day (dose level 2), 300 mg/day (dose level 3), or 400mg/day (dose level 4)] to evaluate the safety and tolerability of the investigational drug (bosutinib) under a 3+3 dose escalation study design. The dose will be escalated by 1 dose level at a time; no skipping will be allowed.

Dose escalation and MTD will be determined by the safety assessment committee comprising oncologist, hematologist, ALS Expert based on the incidence of DLT in 4 weeks of treatment among 3 subjects enrolled (6 subjects if additionaly enrolled) in each dose level. RP2D will be determined by the safety assessment committee upon completion of 12-week study treatment in all subjects in all dose levels.

Phase 2 part:

The phase 2 part consists of 4 periods including a 12-week observation period, a 1-week (±2 days) transitional period, a 24-week study treatment period, and a 4-week safety follow-up period. After the completion of the transitional period, subjects whose total ALSFRS-R score decreased by 1 to 4 points during the 12-week observation period will receive bosutinib treatment during the 24-week study treatment period.

In this study, 25 ALS patients will be enrolled; patients will be randomly assigned to the following groups: 12 patients in 200 mg/day group and 13 patients in 300 mg/daygroup of the investigational drug (bosutinib). The efficacy and the safety of bosutinib in ALS patients for 24 weeks will be assessed. The efficacy using ALSFRS-R score will be also compared with the external published data from edaravone study (MCI186-19). In order to compare with the edaravone study (MCI186-19) , the eligibility criteria of the phase 2 part is similar to those in MCI186-19. By statical allocation, approximately 85% of patients in each 200 mg and 300 mg group will have a decrease of 1-2 points in ALSFRS-R, and 15% will have a decrease of 3-4 points in ALSFRS-R, during the observation period, in accordance with MCI186-19.

The efficacy using ALSFRS-R score will be also compared with matched control of Japanese Consorsium for Amyotrophic Lateral Sclerosis (JaCALS), a registory of ALS, in an exploratory manner.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 49
• Est. completion date: March 31, 2024
• Est. primary completion date: March 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 75 Years

Eligibility

[Phase 1 part]

Inclusion criteria:

1. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study. To be additionaly signed by a delegate signer if the subject is unable to handwrite.

2. Patients aged =20 years and <80 years at the time of informed consent

3. Patients with positive already-reported SOD1 gene mutation and progressive muscle weakness; sporadic ALS patients who are categorized as either "Definite ALS" or "Probable ALS" or "Probable-laboratory supported ALS" in the Updated Awaji Criteria for the diagnosis of ALS

4. Patients at Grade 1 or 2 in the Japan ALS Severity Scale of the grant-in-aid program for chronic diseases from the Japanese Ministry of Health, Labour and Welfare; patients with positive SOD1 mutation of Grade 1, 2 or 3

5. Patients with ALS that occurred within 2 years at the time of the first registration; patients with positive SOD1 mutation within 5 years after disease onset

6. Patients who can visit hospital regularly as outpatients

7. Patients with change in total ALSFRS-R score during the observation period are -1 to -3 points

8. Urine pregnancy test (for females of childbearing potential) negative at screening

Female patients of nonchildbearing potential must meet at least 1 of the following criteria:

1. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state;

2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;

3. Have medically confirmed ovarian failure. All other female patients (including female patients with tubal ligations) are considered to be of childbearing potential.

Male and female patients of childbearing potential must agree to use one highly effective method of contraception as outlined in this protocol, throughout the study and for at least 28 days after the last dose of investigational product.

9. Patients with appropriate renal function as defined as follows at the time of the first and second registrations

a. Serum creatinine =1.5 × upper limit of normal (ULN) or estimated creatinine clearance =60 mL/min as calculated using the method standard for the institution.

10. Patients with appropriate hepatic function as defined as follows at the time of the first and second registrations b. Total serum bilirubin =1.5 × ULN unless the patient has documented Gilbert syndrome; c. AST and ALT =2.5 × ULN

11. Able to take oral tablets

12. Patients whose acute effect of previous treatment has recovered to the baseline or CTCAE v.4.03 = Grade 1 at the time of the first and second registrations

13. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion criteria:

1. Patients with tracheostomy

2. Patients who have used non-invasive ventilation due to ALS symptoms

3. Patients whose %FVCs are less than 70% at the time of first and second registrations

4. Patients who have nerve conduction study findings of demyelination such as conduction block

5. Patients who are taking edaravone; patients who started riluzole or edaravone after start of the observation period; patients who changed the dosage of riluzole after start of the observation period

6. Patients with bulbar type ALS with dysphagia and dysarthria

7. Patients with cognitive impairment

8. Pregnant female patients; breastfeeding female patients; fertile male and female patients of childbearing potential who are unwilling or unable to use 1 highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product

9. History of clinically significant or uncontrolled cardiac disease including:

• History of, or active, congestive heart failure;

• Uncontrolled angina or hypertension within 3 months prior to registration;

• Myocardial infarction within 12 months prior to registration;

• Clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes);

• Diagnosed or suspected congenital or acquired prolonged QT interval history or prolonged QTc (QTcF should not exceed 500 msec);

• Unexplained syncope

10. Uncontrolled hypomagnesemia or uncorrected hypokalemia due to potential effects on the QT interval

11. Patient who is taking the following medicines during study drugs administration.

a Combination of warfarin or other anticoagulation. Combination of therapeutic anticoagulant therapy with low molecular weight heparin is acceptable b Src or c-Abl inhibitors c Other treatments for cancer d Drugs known to prolong the QT interval or predispose to Torsades de Pointe e Current or anticipated use of a strong or moderate CYP3A inhibitor and inducer f Drugs affecting gastric pH such as Proton pump inhibitors (e.g., lansoprazole)

12. History of malignancy within 5 years prior to registration with the exception of basal cell carcinoma or cervical carcinoma in situ or Stage 1 or 2 cancer that is considered adequately treated and currently in complete remission for at least 12 months

13. Patients who were enrolled in other clinical study within 12 weeks before the first registration, or are expected to be enrolled in other clinical study using a study drug during this study

14. Known prior or suspected severe hypersensitivity to study drugs or any component in their formulations

15. Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness

16. Recent or ongoing clinically significant GI disorder (eg, Crohn's disease, ulcerative colitis, or prior total or partial gastrectomy).

17. Patients with chronic obstructive pulmonary disease

18. Major surgery or radiotherapy within 14 days prior to registration at the time of the first registration

19. Patient who fulfills the conditions:

1. Neutrophil count (ANC) <1,500/mm3 or white blood cell <3,000/mm3 at the time of the first and second registration

2. Hemoglobin <9.0 g/dL at the time of the first and second registrations

3. Platelet count <100,000/L at the time of the first and second registrations

20. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study

21. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study

[Phase 2 part]

Inclusion criteria:

1. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study. To be additionally signed by a delegate signer if the subject is unable to handwrite.

2. Patients aged =20 years and =75 years at the time of informed consent

3. ALS patients who are categorized as either "Definite ALS" or "Probable ALS in the El Escorial and revised Airlie House criteria for the diagnosis of ALS

4. Patients at Grade 1 or 2 in the Japan ALS Severity Scale of the grant-in- aid program for chronic diseases from the Japanese Ministry of Health, Labour and Welfare

5. Patients with ALS within 2 years of symptom onset at the time of the first registration

6. Patients with change in total ALSFRS-R score during the observation period from -1 to -4 points

7. Patients with score of at least 2 on all items of ALSFRS-R; 4.Writing, 5.Feeding behavior (1) must have at least 2 points on each side.

8. Urine pregnancy test (for females of childbearing potential) negative at screening

Female patients of nonchildbearing potential must meet at least 1 of the following criteria:

1. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state;

2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;

3. Have medically confirmed ovarian failure. All other female patients (including female patients with tubal ligations) are considered to be of childbearing potential.

9. Patients with appropriate renal function as defined as follows at the time of the first and second registrations

a. Estimated creatinine clearance or eGFR =60 mL/min (mild renal impairment) as calculated using the method standard for the institution (the CKD-EPI equation is recommended, other methods such as Cockcroft-Gault or MDRD may be used. The same method should be applied throughout the study period.).

10. Patients with appropriate hepatic function as defined as follows at the time of the first and second registrations

1. Total serum bilirubin 1.5 × ULN unless the patient has documented Gilbert syndrome;

2. AST and ALT 2.5 × ULN

11. Patients who can consistently take the investigational drug and other oral tablets with water throughout the study period.

12. Patients whose adverse event during previous treatment has recovered to the baseline (Visit 5: before the start of study drug administration) or CTCAE v.4.03 = Grade 1 at the time of the first and second registrations. Excluding the case where the investigator (sub-investigator) judges that the event is not a safety risk.

13. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion criteria:

1. Patients with tracheostomy

2. Patients who had decreased respiratory function and complained of dyspnea at the time of enrollment (One of the three items on the ALSFRS-R related to respiratory (10) dyspnea, (11) orthopnea, or (12) respiratory failure is less than 3 points).

3. Patients whose %FVCs are at least 80 % at the time of first and second registrations

4. Patients who have nerve conduction study findings of demyelination such as conduction block

5. Patients using edaravone within 4 weeks prior to enrollment in the observation period; patients using edaravone at the time of enrollment in the observation period; patients who started edaravone after start of the observation period

6. Patients who started riluzole after start of the observation period; patients who changed the dosage of riluzole after start of the observation period

7. Patients with bulbar-onset type ALS with dysphagia and dysarthria

8. Patients with Parkinson's disease and syndromes, schizophrenia, cognitive impairment, and other comorbidities that may have a significant impact on the evaluation of drug efficacy

9. Patients with a history of spinal surgery such as cervical spondylosis or disc herniation after the onset of ALS, or patients who were scheduled to undergo surgery during the study period

10. Patients whose symptoms could not be ruled out as symptoms of a disease that requires differential diagnosis, such as cervical spondylosis or multifocal motor neuropathy.

11. Pregnant female patients; breastfeeding female patients

12. History of clinically significant or uncontrolled cardiac disease including:

• History of, or active, congestive heart failure;

• Uncontrolled angina or hypertension within 3 months prior to registration;

• Myocardial infarction within 12 months prior to registration;

• Clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes);

• Diagnosed or suspected congenital or acquired prolonged QT interval history or prolonged QTc (QTcF should not exceed 500 msec);

• Unexplained syncope

13. Uncontrolled hypomagnesemia or uncorrected hypokalemia due to potential effects on the QT interval

14. Patient who is taking the following medicines during study drugs administration. Refer to Prohibited Medications.

a Combination of warfarin or other anticoagulation. Combination of low molecular weight heparin is acceptable b Src or c-Abl inhibitors c Drugs known to prolong the QT interval or predispose to Torsades de Pointe d Current or anticipated use of a strong or moderate CYP3A inhibitor and inducer e Drugs affecting gastric pH such as Proton pump inhibitors (e.g., lansoprazole)

15. History of malignancy within 5 years prior to the first registration with the exception of basal cell carcinoma or cervical carcinoma in situ or Stage 1 or 2 cancer that is considered adequately treated and currently in complete remission for at least 12 months

16. Patients who were enrolled in other clinical study within 12 weeks before the first registration, or are expected to be enrolled in other clinical study using a study drug during this study

17. Known prior or suspected severe hypersensitivity to study drugs or any component in their formulations

18. Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness

19. Recent or ongoing clinically significant GI disorder (eg, Crohn's disease, ulcerative colitis, or prior total or partial gastrectomy).

20. Patients with chronic obstructive pulmonary disease

21. Major surgery within 14 days prior to registration at the time of the first registration

22. Patient who fulfills the conditions:

1. Neutrophil count (ANC) <1,500/mm3 or white blood cell <3,000/ mm3 at the time of the first and second registration

2. Hemoglobin <9.0 g/dL at the time of the first and second registrations

3. Platelet count <100,000/µL at the time of the first and second registrations

23. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study

24. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Drug:
• Bosutinib (Phase 1 part)
Subjects will receive 100 mg, 200mg, 300mg or 400 mg of bosutinib once daily, orally.
• Bosutinib (Phase 2 part)
Subjects will receive 200mg/day or 300mg/day of bosutinib once daily, orally.

Locations

Country	Name	City	State
Japan	Hiroshima University	Hiroshima
Japan	Nara Medical University	Kashihara
Japan	Kyoto University	Kyoto
Japan	Kitasato University	Sagamihara
Japan	Tokushima university	Tokushima
Japan	Toho University	Tokyo
Japan	Tottori University	Yonago

Sponsors (8)

Lead Sponsor	Collaborator
Kyoto University	Hiroshima University, Kitasato University, Nara Medical University, Pfizer, Toho University, Tokushima University, Tottori University

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Phase 1 part: Change in total ALSFRS-R score	ALSFRS-R score; ALS Functional Rating Scale-Revised score, the maximum points 48, the minimum points 0, higher scores mean a better outcome.	Up to 12 weeks of treatment with bosutinib
Other	Phase 1 part: Change in the Japan ALS severity classification	Grade 1 to Grade 5, lower grade means a better outcome.	Up to 12 weeks of treatment with bosutinib
Other	Phase 1 part: Change in %FVC	FVC; Forced Vital Capacity Changes from baseline in %FVC	Up to 12 weeks of treatment with bosutinib
Other	Phase 1 part: Change in grip power	Changes from baseline in grip strength	Up to 12 weeks of treatment with bosutinib
Other	Phase 1 part: Change in blood neurofilament L	Change in plasma neurofilament L during the observation period and the study treatment period	Up to 12 weeks of treatment with bosutinib
Other	Phase 1 part: Change in blood phosphorylated neurofilament H	Change in blood phosphorylated neurofilament H during the observation period and the study treatment period	Up to 12 weeks of treatment with bosutinib
Other	Phase 2 part: Change in ALSFRS-R compared with registry data	Change from baseline in ALSFRS-R at week 24 will be compared with external controls matched for clinical background in Japanese Consortium for Amyotrophic Lateral Sclerosis (JaCALS) registry.	Up to 24 weeks of treatment with bosutinib
Other	Phase 2 part: Change in modified Norris Scale	Change from baseline in modified Norris Scale will be compared with those of the placebo group in the edaravone study (MCI186-19).	Up to 24 weeks of treatment with bosutinib
Other	Phase 2 part: Change in ALSAQ-40	Change from baseline in ALSAQ-40 will be compared with those of the placebo group in the edaravone study (MCI186-19).	Up to 24 weeks of treatment with bosutinib
Other	Phase 2 part: Change in %FVC	Change from baseline in %FVC will be compared with those of the placebo group in the edaravone study (MCI186-19).	Up to 24 weeks of treatment with bosutinib
Other	Phase 2 part: Change in grip power	Change from baseline in grip power will be compared with those of the placebo group in the edaravone study (MCI186-19).	Up to 24 weeks of treatment with bosutinib
Other	Phase 2 part: Change in blood neurofilament L	Change in plasma neurofilament L during the study treatment period	Up to 24 weeks of treatment with bosutinib
Primary	Phase 1 part: Dose-limiting toxicity (DLT)	Dose limiting toxity (DLT) for 4 weeks after initiating bosutinib	During the first 4 weeks of treatment with bosutinib
Primary	Phase 1 part: Dose-limiting toxicity (DLT)	Dose limiting toxity (DLT) during all treatment period (12 weeks)	Up to 12 weeks of treatment with bosutinib
Primary	Phase 2 part: Change in ALSFRS-R from baseline to week 24 in each 200mg and 300mg group compared with the external published data of placebo group	Change from baseline in ALSFRS-R at week 24 in each 200mg and 300mg group will be compared with the external published data of placebo group excluded bulbar-onset type in edaravone study (MCI186-19)	Up to 24 weeks of treatment with bosutinib
Primary	Phase 2 part: Adverse events	Safety in each dose group and pooled dose group during 24 weeks of treatment. Adverse events will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v.4.03).	Up to 24 weeks of treatment with bosutinib
Primary	Phase 2 part: Incidence of abnormal laboratory test results	Hematology, Blood chemistry, Coagulation test, etc.	Up to 24 weeks of treatment with bosutinib
Primary	Phase 2 part: Incidence of abnormal vital signs	Blood pressure, Pulse rate, Body temperature	Up to 24 weeks of treatment with bosutinib
Primary	Phase 2 part: Incidence of abnormal ECG recordings	ECG; electrocardiogram	Up to 24 weeks of treatment with bosutinib
Primary	Phase 2 part: Incidence of abnormal X-ray findings	chest X-ray examination	Up to 24 weeks of treatment with bosutinib
Secondary	Phase 1 part: Adverse events	Adverse events are graded based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.4.03.	Up to 12 weeks of treatment with bosutinib
Secondary	Phase 1 part: Incidence of abnormal laboratory test results	Hematology, Blood chemistry, Coagulation test, etc.	Up to 12 weeks of treatment with bosutinib
Secondary	Phase 1 part: Incidence of abnormal vital signs	Blood pressure, Pulse rate, Body temperature	Up to 12 weeks of treatment with bosutinib
Secondary	Phase 1 part: Incidence of abnormal ECG recordings	ECG; electrocardiogram	Up to 12 weeks of treatment with bosutinib
Secondary	Phase 1 part: Incidence of abnormal X-ray findings	chest X-ray examination	Up to 12 weeks of treatment with bosutinib
Secondary	Phase 2 part: Change in ALSFRS-R from baseline to week 24 in combined group of 200 mg and 300 mg group compared with placebo group	Change from baseline in ALSFRS-R at week 24 in combined group of 200 mg and 300 mg group will be compared with the external published data of placebo group excluded bulbar-onset type in edaravone study (MCI186-19)	Up to 24 weeks of treatment with bosutinib
Secondary	Phase 2 part: Change in ALSFRS-R from baseline to week 24 in combined group of 200 mg and 300 mg group compared with edaravone group	Change from baseline in ALSFRS-R at week 24 in combined group of 200 mg and 300 mg group will be compared with the external published data of edaravone group excluded bulbar-onset type in edaravone study (MCI186-19)	Up to 24 weeks of treatment with bosutinib